Hims & Hers Health is betting that the cash-pay market for weight-loss drugs will drive up customer demand although some ...

Approximately 15 million Americans are on a GPL-1 or better known as Ozempic, Wegovy and Zepbound but there will be upcoming ...

Eli Lilly and Company (NYSE:LLY) may be affected by the CVS formulary change considering it could change how its medication, ...

CVS' Health Services segment posts $43B in revenues as specialty pharmacy and Caremark deals drive 2025 growth prospects.

The healthcare sector is dominated by massive players, but few are as influential as UnitedHealth Group Incorporated UNH and ...

CVS Caremark identified GLP-1 drugs and Humira as points of contention, but the State Health Plan says that mischaracterizes ...

Novo Nordisk's Q1 showed robust sales/EPS growth, fueled by soaring GLP-1 demand in a multi-billion dollar market. Read why I ...

Cigna's Express Scripts, one of the big three U.S. pharmacy benefit managers, struck a deal last month in which patients will ...

Adding to the pressure is that CVS Health has retained coverage of Zepbound's arch rival Wegovy (semaglutide), sold by Novo Nordisk, after negotiating a price cut with the company, along with Novo ...

Eli Lilly will ship the two highest doses of its popular weight-loss drug Zepbound to cash-paying customers on its website ...

Earlier this month, Novo announced that CVS Caremark chose Wegovy to be its preferred GLP-1 medication for obesity and weight-loss. 2 This policy will go into effect at the start of July. In a press ...